Retreatment with EGFR-TKIs in Lung Cancer Patients
Author Information
Author(s): Watanabe Satoshi, Tanaka Junta, Ota Takeshi, Kondo Rie, Tanaka Hiroshi, Kagamu Hiroshi, Ichikawa Kosuke, Koshio Jun, Baba Junko, Miyabayashi Takao, Narita Ichiei, Yoshizawa Hirohisa
Primary Institution: Niigata University Medical and Dental Hospital
Hypothesis
Can a second EGFR-TKI treatment be effective for non-small cell lung cancer patients who previously responded to gefitinib?
Conclusion
A second EGFR-TKI treatment can be an effective option for patients who previously benefited from gefitinib therapy.
Supporting Evidence
- 73% of patients achieved disease control with the second EGFR-TKI treatment.
- The median progression-free survival was 3.4 months.
- The median overall survival from the beginning of the second EGFR-TKI was 7.3 months.
Takeaway
This study looked at whether giving a second type of cancer medicine after the first one stopped working could help lung cancer patients who did well on the first medicine.
Methodology
Retrospective analysis of 11 patients who had a partial response or stable disease with gefitinib and were retreated with EGFR-TKI after initial treatment failure.
Limitations
The study is limited by its small sample size and retrospective design.
Participant Demographics
{"total":11,"female":8,"male":3,"median_age":55,"age_range":"46-70","non_smokers":7,"adenocarcinoma":10}
Statistical Information
P-Value
{"PFS":0.23,"OS":0.052}
Confidence Interval
{"DCR":"95% CI, 43% - 91%","median_PFS":"95% CI, 2 - 5.2","median_OS":{"from_2nd_TKI":"95% CI, 2.7 - 13","from_diagnosis":"95% CI, 23.6 - 43.9"}}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website